Our lead small molecule therapeutic candidate, fezagepras (also known as PBI-4050), is being developed for the treatment of diseases characterized by fibrosis, including idiopathic pulmonary fibrosis. Fezagepras is a molecule that modulates the activity of multiple receptors, including FFAR1 and PPAR alpha.

Fezagepras has shown activity in numerous animal models of fibrosis and it has been observed to regulate several cell types involved in the fibrotic pathway, including macrophages, fibroblasts/myofibroblasts and epithelial cells. We have also completed several early phase clinical trials and, to date, fezagepras has been shown to be well tolerated.

We are currently reviewing the most appropriate indications for fezagepras. Future trials are expected after we have established the optimal dose level based on the results of our planned Phase 1 multiple ascending dose trial. To date, fezagepras has been evaluated in human subjects combined across three Phase 1 clinical trials, three open-label Phase 2 clinical trials and one placebo-controlled Phase 2 trial.